A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Study ID
NCT07255898
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BL-M24D1 — DRUG
    Administration by intravenous infusion for a cycle of 2 weeks.

Study Details

This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics characteristics and preliminary efficacy of BL-M24D1 in patients with relapsed or refractory multiple myeloma and other hematologic malignancies.

Key Dates

First listed
Dec 1, 2025
Start date
Mar 25, 2026
Status verified
Jun 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
33 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BL-M24D1
    Participants receive BL-M24D1 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Primary Outcome Measure

Phase Ia: Dose limiting toxicity (DLT) [ Time Frame: Up to 28 days after the first dose ]

Central Contacts

Find similar trials

Nationwide
Multiple myeloma trialsOncology trialsBlood cancer trials

Related Studies